Repligen (NASDAQ: RGEN) Delivers Strong Q1 2026 Results and Positive Analyst Outlook

Font: Financial Modeling Prep  • May 05, 2026

• Repligen reported strong Q1 2026 financial performance, with revenue and EPS surpassing analyst estimates.
• A Jefferies analyst set a positive price target for Repligen, indicating a potential upside for the stock.
• The company increased its full-year adjusted EPS guidance, signaling confidence in its ongoing business execution.

Repligen (NASDAQ: RGEN) is a global bioprocessing company that develops and sells products used in the manufacturing of biological drugs. With a market capitalization of approximately $7.08 billion, Repligen's stock price has seen its value move between $109.50 and $175.77 over the past 52 weeks, indicating notable changes in its market valuation.

Following the company's recent performance, Jefferies analyst Matthew Stanton has lowered the price target for Repligen to $142.00. At the time of the announcement, the stock was trading at $125.61. This new price target represents a potential upside of approximately 13.05%, suggesting a positive outlook on the stock's future value.

This analyst rating comes after Repligen reported strong first-quarter 2026 financial results. As highlighted by GlobeNewswire, the company announced revenue of $194.00 million, a 15% increase from the same period last year. This result continues a trend where the company has exceeded consensus revenue estimates for the past four quarters.

The company’s profitability also grew significantly. As highlighted by Zacks, it posted earnings per share (EPS) of $0.48, surpassing analyst estimates of $0.38. EPS is a measure of a company's profit allocated to each share of stock. Repligen’s adjusted EPS for the quarter rose by 23% compared to the prior year.

Based on these strong results, Repligen has updated its financial guidance for the full year 2026. The company reaffirmed its organic revenue growth forecast of 9% to 13%. It also increased its adjusted EPS guidance to a new range of $1.97 to $2.05, signaling confidence in its ongoing business execution.